The test is now covered for post-menopausal women diagnosed with early-stage breast cancer that has spread to up to three axillary lymph nodes. Before the change in Medicare criteria, the test was covered only if the patient’s lymph nodes had not been affected.
Approximately 25,000 more patients a year are eligible for testing due to broader coverage, according to a May 10 news release.
The Breast Cancer Index test is a molecular, gene expression-based test that facilitates an individualized approach to treatment for patients with early-stage, hormone-receptor positive breast cancer, the news release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
